Compare HYFT & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HYFT | CING |
|---|---|---|
| Founded | 1983 | 2012 |
| Country | United States | United States |
| Employees | 102 | 14 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.9M | 59.3M |
| IPO Year | N/A | N/A |
| Metric | HYFT | CING |
|---|---|---|
| Price | $1.76 | $4.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.00 | ★ $34.50 |
| AVG Volume (30 Days) | 448.7K | ★ 507.2K |
| Earning Date | 03-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $29.18 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.99 | $3.20 |
| 52 Week High | $3.00 | $11.89 |
| Indicator | HYFT | CING |
|---|---|---|
| Relative Strength Index (RSI) | 69.74 | 39.11 |
| Support Level | $1.56 | $3.50 |
| Resistance Level | $1.93 | $4.16 |
| Average True Range (ATR) | 0.16 | 0.49 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 72.15 | 16.61 |
MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.